Overview

Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)

Status:
Not yet recruiting
Trial end date:
2023-02-24
Target enrollment:
Participant gender:
Summary
This is a phase 2A, double-blind, randomized, placebo-controlled study of molnupiravir (MK-4482) in healthy participants who have been inoculated with an experimental Respiratory Syncytial Virus (RSV) [RSV-A Memphis 37b]. It is hypothesized that MK-4482 will reduce the peak viral load (PVL) compared to placebo when given either before (prophylactic) or after (treatment) RSV-A Memphis 37b inoculation. Participants arrive at the study center for check-in between Day -3 and Day -1. The assigned treatment sequence (consisting of a combination of molnupiravir or placebo) begins Day -1. Participants receive viral inoculation with RSV-A Memphis 37b on Day 0, and depart on Day 12. There is a follow-up visit on Day 28.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme LLC